TLR2在消化道肿瘤发生发展中作用的研究进展

doi:10.16352/j.issn.1001-6325.2023.08.1304

基础医学与临床 ›› 2023, Vol. 43 ›› Issue (8): 1304-1308.doi: 10.16352/j.issn.1001-6325.2023.08.1304

TLR2在消化道肿瘤发生发展中作用的研究进展

邹宇祥^1,2, 唐慧^1,2*

1.昆明理工大学医学院,云南昆明 650500;
2.云南省第一人民医院消化内科,云南昆明 650500

收稿日期:2022-07-21 修回日期:2022-12-06 出版日期:2023-08-05 发布日期:2023-07-26
通讯作者: ^*htang1122@aliyun.com
基金资助:
国家自然科学基金(82260483,81502556);云南省科技厅-昆明医科大学应用基础研究联合专项重点项目【2019FE001(-173)】;云南省消化内镜临床医学中心建设项目(2X2019-01-02);云南省卫生科技计划项目(2018NS0245);昆明市肿瘤分子与免疫防治重点实验室基金(2018-1-A-17334)

Research progress on the role of TLR2 in the development of gastrointestinal cancer

ZOU Yuxiang^1,2, TANG Hui^1,2*

1. Medical School, Kunming University of Science and Technology, Kunming 650500;
2. Department of Gastroenterology, the First People's Hospital of Yunnan Province,Kunming 650500, China

Received:2022-07-21 Revised:2022-12-06 Online:2023-08-05 Published:2023-07-26
Contact: ^*htang1122@aliyun.com

摘要/Abstract

摘要： Toll样受体2(TLR2)是一种模式识别受体(PRR),能利用TLR2-MyD88等途径介导机体的免疫与炎性反应、血管生成等生理过程。TLR2表达于细胞表面,可被外源PAMPs及内源DAMPs激活,通过MyD88、PI3K/Akt、Wnt/β-catenin、MAPK等经典与非经典信号途径调节细胞核RNA表达,介导消化道肿瘤发生发展。

关键词: TLR2, 恶性肿瘤, 消化道肿瘤

Abstract: Toll-like receptor 2 (TLR2) is a pattern recognition receptor (PRR) that mediates immune and inflammatory responses, angiogenesis, and other physiological processes using the TLR2-MyD88 pathway. It is expressed on the cell surface, activated by exogenous PAMPs and endogenous DAMPs, and mediates the development of gastrointestinal cancer by regulating nuclear RNA expression through classical and non-classical signaling pathways such as MyD88, PI3K/Akt, Wnt/β-catenin, and MAPK.

Key words: TLR2, cancer, gastrointestinal cancer

中图分类号:

R392.12

邹宇祥, 唐慧. TLR2在消化道肿瘤发生发展中作用的研究进展[J]. 基础医学与临床, 2023, 43(8): 1304-1308.

ZOU Yuxiang, TANG Hui. Research progress on the role of TLR2 in the development of gastrointestinal cancer[J]. Basic & Clinical Medicine, 2023, 43(8): 1304-1308.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal11.magtechjournal.com/Jwk_jcyxylc/CN/10.16352/j.issn.1001-6325.2023.08.1304

http://journal11.magtechjournal.com/Jwk_jcyxylc/CN/Y2023/V43/I8/1304

参考文献

[1]Zheng R, Zhang S, Zeng H, et al. Cancer incidence and mortality in China, 2016[J]. J Natl Cancer Cent, 2022, 2:1-9.
[2]Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71:209-249.
[3]Scheeren FA, Kuo AH, van Weele LJ, et al. A cell-intrinsic role for TLR2-MYD88 in intestinal and breast epithelia and oncogenesis[J]. Nat Cell Biol, 2014, 16:1238-1248.
[4]Martínez A, Bono C, Gozalbo D, et al. TLR2 and dectin-1 signaling in mouse hematopoietic stem and progenitor cells impacts the ability of the antigen presenting cells they produce to activate CD4 T cells[J]. Cells, 2020, 9:1317.doi:10.3390/cells9051317.
[5]Su YR, Chen MT, Xiong K, et al. Endogenous Toll-like receptor 2 modulates Th1/Treg-promoting dendritic cells in mice corneal transplantation model[J]. Curr Eye Res, 2020, 45:774-781.
[6]Nakao M, Sugaya M, Fujita H, et al. TLR2 deficiency exacerbates imiquimod-induced psoriasis-like skin inflammation through decrease in regulatory T cells and impaired IL-10 production[J]. Int J Mol Sci, 2020, 21:8560.doi:10.3390/ijms21228560.
[7]Im J, Baik JE, Lee D, et al. Bacterial lipoproteins induce BAFF production via TLR2/MyD88/JNK signaling pathways in dendritic cells[J]. Front Immunol, 2020, 11:564699.doi:10.3389/fimmu.2020.564699.
[8]Mccoy MG, Nascimento DW, Veleeparambil M, et al. Endothelial TLR2 promotes proangiogenic immune cell recruitment and tumor angiogenesis[J]. Sci Signal, 2021, 14:eabc5371.doi:10.1126/scisignal.abc5371.
[9]Lundy J, Gearing LJ, Gao H, et al. TLR2 activation promotes tumour growth and associates with patient survival and chemotherapy response in pancreatic ductal adenocarcinoma[J]. Oncogene, 2021, 40:6007-6022.
[10]Fan L, Xu C, Ge Q, et al. A. Muciniphila suppresses colorectal tumorigenesis by inducing TLR2/NLRP3-Mediated M1-like TAMs[J]. Cancer Immunol Res, 2021, 9:1111-1124.
[11]Xu J, Guo R, Jia J, et al. Activation of Toll-like receptor 2 enhances peripheral and tumor-infiltrating CD8(+) T cell cytotoxicity in patients with gastric cancer[J]. BMC Immunol, 2021, 22:67.doi:10.1186/s12865-021-00459-z.
[12]Chang YJ, Wu MS, Lin JT, et al. Helicobacter pylori-induced invasion and angiogenesis of gastric cells is mediated by cyclooxygenase-2 induction through TLR2/TLR9 and promoter regulation[J]. J Immunol, 2005, 175:8242-8252.
[13]Zhu G, Cheng Z, Huang Y, et al. MyD88 mediates colorectal cancer cell proliferation, migration and invasion via NF-κB/AP-1 signaling pathway[J]. Int J Mol Med, 2020, 45:131-140.
[14]Xu Z, Lv Z, Chen F, et al. Dysbiosis of human tumor microbiome and aberrant residence of actinomyces in tumor-associated fibroblasts in young-onset colorectal cancer[J]. Front Immunol, 2022, 13:1008975.doi:10.3389/fimmu.2022.1008975.
[15]Liu YD, Ji CB, Li SB, et al. Toll-like receptor 2 stimulation promotes colorectal cancer cell growth via PI3K/Akt and NF-κB signaling pathways[J]. Int Immunopharmacol, 2018, 59:375-383.
[16]Chen X, Zhang L, Jiang Y, et al. Radiotherapy-induced cell death activates paracrine HMGB1-TLR2 signaling and accelerates pancreatic carcinoma metastasis[J]. J Exp Clin Cancer Res, 2018, 37:77.doi:10.1186/s13046-018-0726-2.
[17]Kajino-Sakamoto R, Fujishita T, Taketo MM, et al. Synthetic lethality between MyD88 loss and mutations in Wnt/β-catenin pathway in intestinal tumor epithelial cells[J]. Oncogene, 2021, 40:408-420.
[18]Tang F, Cao F, Lu C, et al. Dvl2 facilitates the coordination of NF-κB and Wnt signaling to promote colitis-associated colorectal progression[J]. Cancer Sci, 2022, 113:565-575.
[19]Zhang S, Wang J, Chen T, et al. α-Actinin1 promotes tumorigenesis and epithelial-mesenchymal transition of gastric cancer via the Akt/GSK3β/β-Catenin pathway[J]. Bioengineered, 2021, 12:5688-5704.
[20]Gao L, Wang TH, Chen CP, et al. Targeting COX-2 potently inhibits proliferation of cancer cells in vivo but not in vitro in cutaneous squamous cell carcinoma[J]. Transl Cancer Res, 2021, 10:2219-2228.
[21]Ma J, Zhang C, Liang W, et al. ω-3 and ω-6 polyunsaturated fatty acids regulate the proliferation, invasion and angiogenesis of gastric cancer through COX/PGE signaling pathway[J]. Front Oncol, 2022, 12:802009.doi:10.3389/fonc.2022.802009.
[22]Wu L, Sun J, Liu L, et al. Anti-toll-like receptor 2 antibody ameliorates hepatic injury, inflammation, fibrosis and steatosis in obesity-related metabolic disorder rats via regulating MAPK and NF-κB pathways[J]. Int Immunopharmacol, 2020, 82:106368.doi:10.1016/j.intimp.2020.106368.
[23]Khedr OMS, El-Sonbaty SM, Moawed FSM, et al. Lactobacillus acidophilus ATCC 4356 exopolysaccharides suppresses mediators of inflammation through the inhibition of TLR2/STAT-3/P38-MAPK pathway in DEN-induced hepatocarcinogenesis in rats[J]. Nutr Cancer, 2022, 74:1037-1047.
[24]Xie X, Lv H, Liu C, et al. HBeAg mediates inflammatory functions of macrophages by TLR2 contributing to hepatic fibrosis[J]. BMC Med, 2021, 19:247.doi:10.1186/s12916-021-02085-3.
[25]Tsoi H, Chu ESH, Zhang X, et al. Peptostreptococcus anaerobius induces intracellular cholesterol biosynthesis in colon cells to induce proliferation and causes dysplasia in mice[J]. Gastroenterology, 2017, 152:1419-1433.
[26]Li S, Li F, Xu L, et al. TLR2 agonist promotes myeloid-derived suppressor cell polarization via Runx1 in hepatocellular carcinoma[J]. Int Immunopharmacol, 2022, 111:109168.doi:10.1016/j.intimp.2022.109168.
[27]Bermudez M, Grabowski M, Murgueitio MS, et al. Biological characterization, mechanistic investigation and structure-activity relationships of chemically stable TLR2 antagonists[J]. Chem Med Chem, 2020, 15:1364-1371.

TLR2在消化道肿瘤发生发展中作用的研究进展

Research progress on the role of TLR2 in the development of gastrointestinal cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 6

编辑推荐

Metrics

本文评价

[1]	李景林郑汪洋李鑫恒李正龙王志东崔云甫姜兴明. lncRNA-CCAT1与消化道肿瘤关系的研究进展[J]. 基础医学与临床, 2018, 38(2): 237-240.
[2]	徐周纬严尚学吴华勋陈镜宇张影魏伟. G蛋白偶联受体激酶2活性和表达的调控及其在恶性肿瘤中的作用[J]. 基础医学与临床, 2017, 37(4): 548-552.
[3]	高增法吴永娜李汛. HACE1的生物学特性及其在恶性肿瘤的研究进展[J]. 基础医学与临床, 2016, 36(3): 396-400.
[4]	高增法吴永娜李汛. ARID1A在恶性肿瘤中的研究进展[J]. 基础医学与临床, 2015, 35(9): 1267-1270.
[5]	陈志刚纪志刚石冰冰严维刚王清海樊华李汉忠刘洋. 2例钙化性肾脏肿物的诊治分析[J]. 基础医学与临床, 2015, 35(9): 1249-1251.
[6]	陈客宏曾灵顾玮黄舒娜刘庆蒋建新. 利用生物信息学技术挑选TLR2基因标签单核苷酸多态性位点[J]. 基础医学与临床, 2010, 30(3): 242-245.